Moderna asks FDA to authorize additional booster shot for all adults The request is much broader than Pfizer's, which sought to authorize a second booster for people over 65. Axios · Mar 18, 2022
Moderna seeks FDA authorization for 4th dose of COVID shot Drugmaker Moderna has asked the Food and Drug Administration to authorize a fourth shot of its COVID-19 vaccine as a booster dose for all adults The Independent UK · Mar 18, 2022
Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years Health Canada has approved Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years. The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union. "Health Canada was… Benzinga · Mar 17, 2022
Alnylam Hits Pfizer, Moderna With Patent Infringement Suits Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has filed separate lawsuits in the Delaware federal court against Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA), seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Alnylam said it was seeking compensation for the use of its lipid nanoparticles (LNP) technology that carries and delivers… Benzinga · Mar 17, 2022
Here's Why Moderna Shares Are Rising Moderna Inc (NASDAQ: MRNA) shares are trading higher by 7.0% at $158.42. The company announced today it has reached an agreement with Japan to supply an additional 70 million doses of its COVID-19 booster vaccine. Benzinga · Mar 16, 2022
Psyched: Albert Labs Goes Public, Ex-Moderna Executive Joins MAPS, Novamind and Usona Join For Phase 2 Psilocybin Trial A new company has entered the public psychedelic markets, with an alternative drug-to-market approach. Using Real World Evidence trials, Albert Labs is expecting to legally provide psilocybin to patients in the UK much earlier than companies working with to get FDA approval. Benzinga · Mar 15, 2022
Moderna Moves Forward With Second HIV Vaccine Trial Moderna Inc (NASDAQ:MRNA) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble… Benzinga · Mar 14, 2022
What Are Whales Doing With Moderna A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 59 strange trades. Benzinga · Mar 14, 2022
Here's Why Moderna Shares Are Rising On Monday Moderna Inc (NASDAQ: MRNA) shares are trading higher by 18.9% at $164.27 after the company announced the first participant has been dosed in a clinical trial of an experimental HIV trimer mRNA vaccine. Benzinga · Mar 14, 2022
How drug companies are sidestepping the WHO's technology transfer hub in Africa Pharmaceutical company Moderna announced on 7 March 2022 that it would develop a site in Kenya to manufacture COVID-19 vaccines. The company holds much of the key intellectual property relating to the messenger RNA (mRNA) vaccines. Due to their higher efficacy, mRNA vaccines are the preferred option in developed countries.… The Conversation · Mar 13, 2022
Moderna co-founder Robert Langer: ‘I wanted to use my chemical engineering to help people’ The celebrated US scientist and inventor on not being in it for the money, why diversity improves problem-solving, and his dedication to exercising The Guardian - UK · Mar 12, 2022
University of Queensland researchers partner with Moderna to create fast-tracked, potentially 'game-changing' vaccines Queensland researchers are set to partner with biotechnology company Moderna to fast-track the development of vaccines against some of the world's biggest health threats. ABC News · Mar 10, 2022
Moderna Starts Dosing In Mid-Stage Omicron-Specific Bivalent Booster Candidate Moderna Inc (NASDAQ: MRNA) has Benzinga · Mar 10, 2022
Vacunados con J&J, reforzados con ARNm, y pensando en la tercera dosis Sí, todos estamos agotados por la pandemia de covid. Desconcertados por los constantes cambios en la ciencia y en las directrices. Preocupados por la sucesión de nuevas y temibles variantes, cada una con su propio nombre, como los huracanes. Tribune News Service · Mar 9, 2022
Benzinga · Mar 9, 2022 Check Out What Whales Are Doing With MRNA A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 40 strange trades.
Benzinga · Mar 9, 2022 Chart Wars: Between Moderna And Novavax, Which COVID Stock Will Soar Higher? Moderna, Inc (NASDAQ: MRNA) and Novavax, Inc (NASDAQ: NVAX) were trading up over 10% and 8%, respectively, at one point on Wednesday, boosted by the S&P 500’s almost 2.6% intraday gain.
Benzinga · Mar 9, 2022 'This Stock Could Easily Go To $200': Why Josh Brown Bought Moderna Shares Ritholtz Wealth Management's Josh Brown has managed to successfully catch another falling knife — at least short term.
Benzinga · Mar 8, 2022 Former Moderna Vice President Joins Psychedelics Company In Phase 3 Trials For Ecstasy Michael Mullette, a former Moderna (NASDAQ:MNRA) vice president is taking a senior leadership position in the MAPS Public Benefit Corporation, a biotech company in the psychedelics sector. The MAPS PCB is a for-profit company wholly owned by the Multidisciplinary Association for Psychedelic Studies, a nonprofit founded in 1986 to advance patient…
Radio France Internationale · Mar 8, 2022 US company Moderna signs agreement to build Covid vaccine factory in Kenya US vaccine maker Moderna announced Monday that it would build its first mRNA jab-manufacturing facility in Africa after signing an agreement with Kenya's government to produce up to 500 million doses a year.
Benzinga · Mar 8, 2022 Moderna Plans Vaccines Against 15 Pathogens With Future Pandemic Potential Moderna Inc (NASDAQ: MRNA) plans to develop and begin testing vaccines targeting 15 pathogens identified as the biggest public health risk by WHO and CEPI by 2025. The Company also said it would permanently wave its COVID-19 vaccine patents for shots intended for certain low- and middle-income countries. At its global public health strategy,…
Benzinga · Mar 8, 2022 The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · Mar 7, 2022 Moderna To Set Up mRNA Vaccine Manufacturing Facility In Kenya Moderna Inc (NASDAQ:MRNA) would set up a manufacturing facility in Kenya, its first in Africa, to produce messenger RNA (mRNA) vaccines, including COVID-19 shots. Moderna expects to invest about $500 million in the Kenyan facility and supply as many as 500 million doses of mRNA vaccines to the continent each year. It also…
The Independent UK · Mar 7, 2022 Moderna signs with Kenya for first mRNA facility in Africa Moderna says it has signed a memorandum of understanding with Kenya’s government for the drugmaker's first mRNA vaccine manufacturing facility in Africa
Benzinga · Mar 4, 2022 Moderna Whale Trades Spotted A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 43 strange trades.
Benzinga · Mar 3, 2022 Moderna Whale Trades Spotted A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 18 strange trades.